Abstract. In 14 patients with Addison's disease plasma levels of ACTH were studied after administration of a single oral dose (16 mg) of cyproheptadine. The drug administration was followed by an inhibition of ACTH release.
Since the report of Krieger et al. (1975) (Copinschi et al. 1977; Ambrosi et al. 1979; Kummer et al. 1979; Lankford et al. 1981 ).
The effectiveness of cyproheptadine was related to its antiserotonin effect (Krieger et al. 1975) , although it was recognized that it possesses anticholinergic, anti-histaminergic and anti-dopaminergic effects as well (Stone et al. 1961 ; Gilbert & Goldberg 1975 ).
There are limited data available with regard to the effect of cyproheptadine on pituitary-adrenal activity in normal men : most of these would sup¬ port an inhibitory effect of cyproheptadine on stimulated cortisol and/or ACTH secretion.
The administration of cyproheptadine has been shown to reduce vasopressin-induced (Winkel¬ mann et al. 1977) or hypoglycaemia-induced corti¬ sol secretion (Plonk et al. 1974) and ACTH re¬ sponse to metyrapone in normal men (Plonk & Feldman 1976 ). between the two studies (*P < 0.05 ; **P < 0.01 ).
than basal value through the end of the experi¬ ment. Mean plasma ACTH concentrations after cyproheptadine administration were significantly lower than those after placebo (Table 1) .
The mean per cent changes in ACTH concentra¬ tions from baseline after cyproheptadine were significantly greater than those after placebo ad¬ ministration (Fig. 1) .
All subjects experienced slight sleepiness as a main side-effect from cyproheptadine. Cyproheptadine is classified as a serotonin recep¬ tor antagonist (Douglas 1980) however since the specificity of its action is not established the inter¬ pretation of the current results can only be specula¬ tive.
It has been demonstrated that cyproheptadine, besides anti-serotonin properties, possesses weak anti-cholinergic, anti-histaminergic as well as antidopaminergic effects (Stone et al. 1961; Gilbert 8c Goldberg 1975).
Evidence has been obtained suggesting a role for acetylcoline as putative neurotransmitter involved in CRF-ACTH release (Jones et al. 1976 (Jones et al. , 1979 : due to the very mild anti-cholinergic activity of cyproheptadine (Stone et al. 1961) , it seems un¬ likely that the inhibitory effect of cyproheptadine on ACTH secretion recorded in our patients is an anti-cholinergic one.
On the other hand the present data could hardly be accounted for by an anti-dopaminergic activity of cyproheptadine because our previous results show that dopamine infusion induces a marked fall in ACTH levels in patients with Addison's disease, whereas sulpiride, a dopaminergic receptor anta¬ gonist, has no effect on plasma ACTH in the same subjects nor does it affect dopamine-induced ACTH reduction (Silvestrini et al. 1980 Despite these reservations, data on animals seem to provide evidence that serotonin is involved in the regulation of ACTH secretion (Jones et al. 1976 (Jones et al. , 1979 Krieger 1977 (Allolio etal. 1981) .
